Our Impact. Results, not rhetoric.

Recent wins include a $258.4M Medicaid physician-parity increase raising Louisiana Medicaid reimbursement from roughly 73% to 85% of Medicare (SFY 2025-26), a 25% Medicaid rate increase for substance-use disorder services — the first in over a decade — Louisiana's first-in-the-nation prior authorization reform (Act 706, 2026) for generic specialist prescriptions, expansion of telehealth access to rural and underserved parishes, and a mandate requiring insurance coverage of biomarker testing for earlier cancer diagnosis.

Yes. Founder Stephen Wright created Louisiana's Rare Disease Advisory Council (Act 321, 2021) — the state's permanent forum for rare-disease patient access — led the addition of Spinal Muscular Atrophy, MPS I, and Pompe disease to the state's Newborn Screening Panel, and led orphan-drug coverage efforts at the state and federal level.

Yes. The firm deployed the physician advocacy critical to Louisiana's SFY 2025-26 Medicaid physician-parity increase — $258.4M in new annual funding raising reimbursement from ~73% to 85% of Medicare (a 16.4% aggregate increase). It also led the first Louisiana Medicaid reimbursement rate increase for substance-use disorder services in more than a decade (25%), secured a stand-alone Medicaid funding code for pregnant women in addiction treatment, and led the mandate for behavioral health insurance parity.

Yes. Louisiana passed Act 791 of 2024 (HB 888), effective August 1, 2024, adopting the Social Work Licensure Compact — letting Louisiana-licensed social workers practice across member states and expanding the behavioral-health workforce for rural, telehealth, and military-family care.

Yes. The firm advised the Louisiana bioscience-industry association whose member firms secured 145 federal SBIR / STTR research awards in the five years following our innovation-fund advocacy — up from 54 in the prior five-year period — including startups developing novel non-opioid pain therapies and advanced regenerative wound-care technologies. The firm led the state biomarker-testing insurance mandate, drafted and led advocacy for Louisiana's 2022 Small Business Innovation Recruitment and Retention Funds (Acts 476 & 477), and successfully advocated to preserve and reinvigorate Louisiana's R&D Tax Credit and Angel Investor Tax Credit programs — key non-dilutive capital pathways for bioscience startups.

Yes, across multiple Gulf South states. The firm represented clients central to a 2022 Mississippi Public Service Commission order creating that state's first rooftop solar rebate program, a related net-metering rule change letting Mississippi public school districts add solar at no upfront cost, the 2026 New Orleans City Council approval of the New Orleans community-solar program (a 60-megawatt pipeline), and the defeat of a 2022 Louisiana legislative push that would have stripped solar and wind projects of Industrial Tax Exemption Program eligibility.

Yes. At the firm's request, on behalf of a client, Louisiana enacted House Bill 701 (2020) as Act 341, creating the state's first licensing framework for virtual-currency businesses and making Louisiana the second state in the nation, after New York, to adopt one.